Robert Gross, MD, MSCE

faculty photo
Professor of Medicine
Attending Physician, Infectious Diseases, Corporal Michael J. Crescenz Veterans Affairs Medical Center
Member, Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine
Senior Fellow, Leonard Davis Institute, University of Pennsylvania, Perelman School of Medicine
Co-Director, Clinical Core, Penn Center for AIDS Research (CFAR) Perelman School of Medicine
Co-Director, Clinical Assessment Core, Penn Mental Health in AIDS Research Center
Senior Fellow , Center for Public Health Initiatives (CPHI), Perelman School of Medicine
Co-Director , Penn Center for AIDS Research, Perelman School of Medicine
Director, International Core, Penn Center for AIDS Research, International Core
Center for Global Health Scholar, University of Pennsylvania Perelman School of Medicine
Department: Medicine

Contact information
804 Blockley Hall
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania, Perelman School of Medicine
423 Guardian Drive
Philadelphia, PA 19104-6021
Office: 215-898-2437
Fax: 215-573-5315
BA (Italian)
Cornell University , 1986.
Cornell University, 1991.
MSCE (Pharmacoepidemiology)
University of Pennsylvania, 2000.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

HIV clinical epidemiology; outcomes of HIV treatment; adherence to therapy including development of methods to measure adherence

Description of Clinical Expertise

HIV; infectious diseases

Selected Publications

O'Brien TC, Feinberg J, Gross R, Albarracin D: Supportive environments during the substance use disorder epidemic in the rural United States: Provider support for interventions and expectations of interactions with providers. Social Science & Medicine 2022 (in press).

Hoskins K, Sanchez AL, Hoffacker C, Momplaisir F, Gross R, Brady KA, Pettit AR, Zengraf K, Mills C, Coley D, Beidas RS : Implementation Mapping to Plan for a Hybrid Trial Testing the Effectiveness and Implementation of a Behavioral Intervention for HIV Medication Adherence and Care Retention. Frontiers in Public Health 2022 (in press).

Sanchez AL, Hoskins K, Pettit AR, Momplaisir F, Gross R, Brady KA, Hoffacker C, Zentgraf K, Beidas RS: Stakeholder Perspectives on Implementing an Evidence-Based Behavioral Intervention for People with HIV: A Rapid Qualitative Analysis of Implementation Determinants JAIDS 2022 (in press).

Martei YM, Narasimhamurthy M, Setlhako DI, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman LN, Grover S, DeMichele A : Relative Dose Intensity and Pathologic Response Rates in Breast Cancer Patients with and without HIV Who Received Neoadjuvant Chemotherapy JCO Global Oncology 2022 (in press).

Motlokwa PK, Tsima BM, Martei YM, Ralefala T, Galebole F, Stephens-Shields AJ, Grover S,* Gross R* * equal contribution by authors : Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting in Sub-Saharan Africa JCO Global Oncology 2022 (in press).

Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B for the A5288 Study team: Third-line antiretroviral therapy including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR) is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings: ACTG A5288 strategy trial. Journal of the International AIDS Society 2022 (in press).

Mannathoko N, Mosepele M, Gross R, Smith R, Alby K, Glaser L,Richard-Greenblatt M, Sharma A,Jaskowiak-Barr A, Cressman L, Sewawa K, Cowden L, Reesey E, Otukile D, Paganotti G, Mokomane M, Lautenbach E : Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) and Carbapenem-Resistant Enterobacterales (CRE) in Healthcare and Community Settings in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study International Journal of Infectious Diseases 2022 (in press).

Mantshonyane L, Kgwaadira B, Gross R: The absence of evidence of cure is not a risk for recurrent tuberculosis among patients treated for TB in Botswana. International Journal of Tuberculosis and Lung Disease 2021 (in press).

Davey S, Grover S, Bilker WB, Setlhako DI, Ralefala TB, Manshimba P, Gross R, DeMichele A, Shulman LN, Martei YM: Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana. BMJ Open 2021 (in press).

Mantshonyane L, Roy J, Levy MZ, Wallis CL, Bar K, Godfrey C, Collier A, LaRosa A, Zheng L, Sun X, Gross R: Participants switching to second-line antiretroviral therapy with susceptible virus display inferior adherence and worse outcomes: an observational analysis of prospectively collected data AIDS Patient Care and STDs 2021 (in press).

back to top
Last updated: 07/05/2022
The Trustees of the University of Pennsylvania